After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

A private boarding school in rural western Massachusetts that opened in the 19th century is receiving a $50 million bequest ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...